



UMBI
UNIVERSITY OF MARYLAND
BIOTECHNOLOGY INSTITUTE

Contact:
Daniel Kuebbing
(240) 314-6350
kuebbing@umbi.umd.edu

May 15, 2007
For Immediate Release

Open House for New UMBI GMP Facility

Rockville, MD – The University of Maryland Biotechnology Institute will host an open house marking the opening of its new Good Manufacturing Practice (GMP) facility at its newly expanded Shady Grove campus in Rockville, MD. The event, to take place on May 23 at 1:00 P.M., will provide an opportunity to learn about the capabilities of the new facility. Individuals interested in attending the open house can contact the facility director, Dr. Daniel Kuebbing, directly, or can RSVP on the web at <https://carb.umbi.umd.edu/gmp>.



GMP facilities are designed to provide the extremely high standards of cleanliness, quality control and documentation that are required for materials intended for use in human clinical trials. This has posed a significant barrier to doing business, particularly for smaller biotechnology and biopharmaceutical companies, which do not generally have the resources to commit to the time and expense associated with building their own GMP facilities.

The new UMBI GMP facility at Shady Grove offers an unprecedented opportunity for the burgeoning Maryland biotechnology industry, by dramatically lowering the costs and difficulties ordinarily associated with GMP-based research and development and clinical trials.

“Our mission is simply to provide an extraordinary, state of the art clinical trial manufacturing facility”, said Dr. Daniel Kuebbing, Director of UMBI’s GMP Training and Biomanufacturing Program. “We are here to support the Biotech industry by offering training, contract manufacturing, and process development.”

The capabilities of the new facility include production of therapeutic proteins, nucleic acids and nanoparticles for pre-clinical testing or Phase I clinical trials. Facility personnel are available to assist in the development of advanced production and separation technologies.

The facilities include 6,000 square feet of clean rooms for the production of clinical trial materials by means of cell culture or fermentation. In addition 1,200 square feet of quality-control laboratory space support production and assay development. An additional 2,000 square feet of wet lab space are available for process development and training. Other areas include office and storage space.

By offering a training program, scheduled to begin in June, the GMP program is directly addressing one of the most challenging problems in biotechnology and biopharma today: the difficulty in finding personnel with the advanced, specialized training in regulatory compliance and operation required by modern operations.

With research centers in Baltimore, Rockville, and College Park, the University of Maryland Biotechnology Institute is the newest of 13 institutions forming the University System of Maryland. UMBI has 85 ladder-ranked faculty and a 2006 budget of \$60 million. Celebrating the institution’s 20th year of service to Maryland and the world, UMBI is led by microbiologist and former biotechnology executive Dr. Jennie C. Hunter-Cevera. For more information visit www.umbi.umd.edu.

###